Overview

Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations

Status:
Completed
Trial end date:
2017-12-11
Target enrollment:
Participant gender:
Summary
This study will test if local therapies in addition to erlotinib can improve responses and delay the time until new treatment is required. This study will also collect blood samples for research blood tests.
Phase:
N/A
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Treatments:
Erlotinib Hydrochloride